Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
21 mars 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h01 HE
|
Travere Therapeutics, Inc.
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
Travere Therapeutics Provides Corporate Update and 2021 Outlook
11 janv. 2021 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
30 nov. 2020 16h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...